Clinical Trial Update: Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Monalizumab in combination with Cetuximab versus Cetuximab alone in recurrent or metastatic head and neck squamous cell carcinoma has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ERBITUX (cetuximab)
• Monalizumab (monalizumab)

Snippet

Sponsor: AstraZeneca | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-11-18